A current buzz phrase in pharmaceutical research right now is “drug-drug interaction” or simply “drug interaction”. The definition of a drug-drug interaction has fluctuated over the last few years, not…
During the first week of December 2007, the European Federation for Pharmaceutical Sciences (EUFEPS) and BioSim, the major European Network of Excellence on Systems Biology, held a challenging conference on…
This is a summary report of the EUFEPS & COST B25 conference on Bioavailability and Bioequivalence which focused on physiological factors and variability. This conference was held at The Royal…
The benefits of modeling and simulation fall into two categories: Increased certainty in trial designs and faster decisions to kill or advance compounds. The first, more tactical benefit means trials…
Recently, metabolic drug-drug interactions (M-DDI) have raised some high-profile problems in drug development resulting in restricted use, withdrawal or non-approval by regulatory agencies. The use of in vitro technologies to evaluate the potential for M-DDI…
© 2025 Certara. 保留所有权力。 | 隐私政策
